MNG765
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.399
- PROTEIN_SECRETION+0.395
- INTERFERON_GAMMA_RESPONSE+0.348
- ALLOGRAFT_REJECTION+0.320
- MYC_TARGETS_V2+0.293
- MYC_TARGETS_V1+0.282
- UV_RESPONSE_DN+0.249
- IL6_JAK_STAT3_SIGNALING+0.248
- TGF_BETA_SIGNALING+0.217
- MITOTIC_SPINDLE+0.203
Top 10 suppressed
- ANGIOGENESIS-0.350
- PANCREAS_BETA_CELLS-0.280
- E2F_TARGETS-0.253
- G2M_CHECKPOINT-0.243
- MTORC1_SIGNALING-0.235
- CHOLESTEROL_HOMEOSTASIS-0.185
- TNFA_SIGNALING_VIA_NFKB-0.170
- GLYCOLYSIS-0.163
- ESTROGEN_RESPONSE_LATE-0.151
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.127
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1218 | — | — | 0.764 |
| 2 | MNG1060 | — | — | 0.740 |
| 3 | SRR10842369 | — | — | 0.732 |
| 4 | MNG678 | — | — | 0.720 |
| 5 | MNG958 | — | — | 0.711 |
| 6 | MNG1199 | — | — | 0.709 |
| 7 | BS_TYKJ8G2G | Schwannoma | — | 0.690 |
| 8 | MNG406 | — | — | 0.687 |
| 9 | SRR26320064 | — | — | 0.680 |
| 10 | MNG784 | — | — | 0.678 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.399 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.395 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.348 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.320 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.293 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.282 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.249 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.248 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.217 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.203 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.194 | Idelalisib | — uncovered |
| PEROXISOME | 0.167 | Idelalisib | — uncovered |
| COAGULATION | 0.166 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.155 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.147 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.139 | Idelalisib | — uncovered |
| APOPTOSIS | 0.104 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.098 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.091 | Temsirolimus | — uncovered |
| ANDROGEN_RESPONSE | 0.090 | Inavolisib | — uncovered |